Market open
Citius Oncology/$CTOR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Citius Oncology
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Ticker
$CTOR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
-
Citius Oncology Metrics
BasicAdvanced
$51M
-
-$0.33
-0.61
-
Price and volume
Market cap
$51M
Beta
-0.61
52-week high
$1.21
52-week low
$0.55
Financial strength
Current ratio
0.394
Long term debt to equity
9.204
Total debt to equity
9.204
Management effectiveness
Return on assets (TTM)
-20.24%
Return on equity (TTM)
-72.11%
Valuation
Price to book
1.24
Price to tangible book (TTM)
1.24
Price to free cash flow (TTM)
-10.16
Growth
Earnings per share change (TTM)
44.85%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Citius Oncology stock?
Citius Oncology (CTOR) has a market cap of $51M as of April 08, 2025.
What is the P/E ratio for Citius Oncology stock?
The price to earnings (P/E) ratio for Citius Oncology (CTOR) stock is 0 as of April 08, 2025.
Does Citius Oncology stock pay dividends?
No, Citius Oncology (CTOR) stock does not pay dividends to its shareholders as of April 08, 2025.
When is the next Citius Oncology dividend payment date?
Citius Oncology (CTOR) stock does not pay dividends to its shareholders.
What is the beta indicator for Citius Oncology?
Citius Oncology (CTOR) has a beta rating of -0.61. This means that it has an inverse relation to market volatility.